Lilly rides Mounjaro, Zepbound to better
Time:2024-05-21 21:00:52 Source:politicsViews(143)
Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Previous:Padres second baseman Xander Bogaerts leaves game against Braves with shoulder injury
Next:Israeli army says it kills over 130 militants in E. Rafah
You may also like
- Amal Clooney played key role in ICC bid to request arrest warrants for Israeli PM and Hamas leader
- Former cruise ship worker reveals the six things she would NEVER do on board
- Second juror in New Hampshire youth center abuse trial explains verdict, says state misinterpreted
- Chad holds presidential election after years of military rule
- Sale continues dominant run as Braves beat Padres 3
- Kyle Larson and Denny Hamlin, the dominant NASCAR Cup Series drivers, could have a blooming rivalry
- Emily Andre shares sweet snap breastfeeding her baby daughter in hospital as she thanks midwives
- Berkshire Hathaway event gives good view of Warren Buffett's successor
- Germany's foreign minister visits Kyiv as Ukraine battles to hold off a Russian offensive